Posted on

Autistic children try microdosing at a psychedelic farmer’s market: issue 20

Here’s what’s in store for you in today’s issue:

🍄Autistic children try microdosing

🍄 Group psychedelic therapy cures depression

🍄 Psychedelic farmer’s markets?

🍄 DMT granted innovative medicine designation

🍄 And more.

You’ll want to stay till the end to learn how someone found enlightenment on a trippy hike.

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast:
The Truth About Psilocybin and the Brain

Julia Joyes is a neuroscientist and research director at TheraPsil, a leading non profit organization making a difference to mental health in Canada. In this episode, we take a closer look at psilocybin’s impact on the brain. 

Therapeutic banner

The first study investigating psilocybin’s impact on children

According to preclinical research conducted by Nova Mentis (NOVA), psilocybin has potential to reduce anxiety in autistic patients and could improve cognitive function in patients with fragile x syndrome (FXS), a genetic condition that causes learning impairments.

Now, the company is forming a joint venture with Mycrodose Therapeutics to accelerate R&D into the treatment. The partnership will use Mycrodose Therapeutics’ patented systems to deliver a self-administered and non-invasive microdose.

The joint venture plans to conduct human clinical trials on a broad range of patients with FXS and autism, including pediatric patients. This will be the first study investigating psilocybin’s impact on children.

Group psychedelic therapy cures depression!

On Tuesday, Compass Pathways (CMPS) received a US patent for COMP360, its proprietary formulation of crystalline psilocybin. On Wednesday, the company announced positive findings from an open-label study using the formulation to treat depression in cancer patients.

Thirty patients were administered COMP360 in group therapy sessions of two to four people. Twenty-four people experienced at least a 50% reduction in depression symptoms within three weeks of treatment, which was sustained at week eight, and fifteen people were in total remission from depression.

The average depression score dropped from 25.9 to just 6.8!

The company notes that the study was not blinded or placebo-controlled, so the findings are subject to expectancy bias, but the results show promise that both COMP360 and group therapy models are effective.

Trip your way to a healthier lifestyle

Psychedelics improve mental health, but can that translate into better physical health too?

A recent study found that people who have tried psychedelics at least once in their life had a 23% lower chance of heart disease and a 12% lower chance of diabetes in the past year.

Other research indicates that psychedelic use is tied to healthier lifestyle choices such as increased exercise, reduced smoking and alcohol consumption, and a balanced diet.

Researchers also theorize that psychedelics could stimulate brain receptors that are linked to both mental and cardiometabolic health.

inspirational banner

DMT receives innovative medicine designation

DMT-assisted therapy could be approved in the UK sooner than expected!

Yesterday, Small Pharma (DMT) received an Innovation Passport Designation for its DMT-assisted therapy program for depression – a status given to promising medicines to expedite development. The passport gives the company access to the Innovative Licensing and Access Pathway (ILAP) to reduce time to market and facilitate patient access to the treatment.

The designation is essentially the UK’s version of a Breakthrough Therapy Designation, which the FDA granted to Compass Pathways (CMPS) and Usona Institute in 2018 and 2019, respectively, for their psilocybin-assisted therapy programs.

Small Pharma also launched a Phase 2a clinical trial for DMT-assisted therapy on Tuesday and began trading on the OTCQB market on Wednesday under the symbol “DMTTF”.

The largest psychedelic event in history

Curious about the latest advancements in psychedelic medicine, psychedelic retreats, microdosing, or the role of technology in the psychedelics sector? Then you won’t want to miss Microdose HQ’s Wonderland: Miami – the largest psychedelic medicine business event to date!

The two-day event on Nov. 8-9 will have keynote presentations from some of the biggest names in the psychedelic sector including including Robin Carhart-Harris, Matthew W. Johnson, Rick Doblin, and David Nutt.

(Mike Tyson and Lamar Odon will also share their experiences with psychedelic healing!)

The speakers will cover a vast range of unique topics: 

  • Shamanic protocols for making investment decisions…
  • Psychedelics and sports…
  • The threat of corporate domination in the industry…
  • And more.

Get your your ticket or virtual access pass here!

business banner

Be an early investor 🤑

Want to be an early investor in a psychedelics company? Now’s your chance!

Ei.Ventures is currently looking to raise $50M through a Regulation A+ Framework – a type of offering that allows the general public, not just institutional or accredited investors, to buy shares in a company before it goes public.

“I’m really passionate about democratizing investment opportunities so any investor can reap the rewards, and take all of the risks of early investment in game-changing companies,” said David Nikzad, the company’s founder, who was an early investor in Airbnb , Betterment, and Vidyard.

Ei.Ventures is developing a transdermal psilocybin patch and is preparing to launch a functional mushroom line early next year. Shares are selling for $4.94 each with a minimum purchase of 101 shares, and the company has already raised $20M. Take advantage of the offer here.

The world’s biggest psychedelic therapy provider

Field Trip Health (FTRP) just got one step closer to reaching its goal of running 75 psychedelic therapy clinics by 2024.

The company opened three new treatment centers in Seattle, Vancouver and Fredericton. It now administers ketamine-assisted therapy at eight clinics across North America and one in Amsterdam.

The treatment is proving to be effective with clients’ depression scores dropping from an average of 17 (severe) to 6 (mild) and benefits lasting at least 120 days.

74 studies on 50 compounds 🤯

This week, Cybin Inc. (CYBN) completed its 74th preclinical study to advance its proprietary molecules, CYB003 and CYB004, toward clinical research.

The company has evaluated 50 novel compounds in its preclinical research, narrowing it down to four lead candidates. including CYB003 for alcohol use disorder and CYB004 for anxiety disorders.

Compared to classic psychedelics, the formulations are showing:

  • Faster onset times
  • Shorter durations
  • High oral bioavailability
  • Significant brain penetration, and
  • Less variability between subjects

Human clinical trials are expected to begin early next year to work toward an Investigational New Drug (IND) status.

legal banner

Psychedelic farmer’s markets coming to Cali!

Oakland could legalize the sale of psychedelics as early as next year!

The city decriminalized the use and cultivation of many psychedelics back in 2019, and now, activists are building on their progress with a “Go Local” Legislative Initiative. The initiative would create a community-based model to allow people to legally purchase natural psychedelics like psilocybin and ayahuasca from local producers.

The initiative will gather research on how best to implement the model over the next year and will introduce a legislation in the summer of 2022.

Some possible reforms being considered include allowing commercial agriculture in residential zones, creating “sacred plant adult farmer’s market permits,” and allowing cannabis dispensaries with 100% local ownership to sell entheogens, among many others.

All products would have to be grown, produced, and tested locally.

Another unanimous win 🎉

After yet another unanimous vote, Easthampton became the fourth city in Massachusetts to decriminalize possession and cultivation of psychedelics!

Will this European island legalize shrooms?

Malta may legalize cannabis, but residents don’t want the reforms to stop there.

In a recent survey, 447 people in Malta were asked if they think the country should legalize any other substances beyond cannabis. Magic mushrooms was the most popular response with 45% in favour of its legalization.

LSD was the next most common response at 27%, but 56% did not see a need for any other drugs to be legalized.

Industry Quick Hits

Oct 18 – Johns Hopkins Receives $4M from the NIH – The First Federal Grant for Psychedelic Research in 50 years Read more…

Oct 19 – FSD Pharma (HUGE) Signs Agreement With Covar Pharmaceuticals To Support The Development Of Lucid-Psych Read more…

Oct 19 – Psyched Wellness (PSYC) says preliminary data reveals potential new functional property of Amanita mushroom for treating skin conditions Read more…

Oct 19 – Bank Of America Shuts Down Account Of Cannabis & Psychedelics Research Institute Registered With DEA Read more…

Oct 19 – atai Life Sciences (ATAI) Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change Read more…

Oct 20 – Tryp Therapeutics (TRYP) Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders Read more… 

Oct 20 – LOVE Pharma (LUV) Announces Development of Muco-Adhesive Sublingual Psilocybin Strip Read more…

Oct 21 – Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific (BRAX) CEO Dr. Roger McIntyre Read more…

Oct 22 – Novamind (NM) Unveils Stealth Mode Investment in Alto Neuroscience Read more…

Video of the Week

Dr. Bronner’s Support for Psychedelic-Assisted Therapy and Plant Medicines

Playlist of the Week

Lo-Fi | psychedleia
mushrooms on scale
Posted on

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

NEW YORK, Oct. 18, 2021 /PRNewswire/ — Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

REGISTER OR LOGIN NOW AT: https://bit.ly/3acCV7Y

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.

Presentations

Presentation Ticker(s)
Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation
“Investing in Psychedelics and CNS Treatments”       Lindsay Hoover, Partner, JLS Fund       Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL), AdvisorShares Investments       Tim Regan, SVP, KCSA Strategic Communications
Small Pharma Inc. (Pink: DMTTF | TSX-V: DMT)
Awakn Life Sciences Corp. (OTCQB: AWKNF | NEO: AWKN)
HMNC Brain Health (Private Company)
Enveric Biosciences (NASDAQ: ENVB)
Mind Cure Health Inc. (OTCQX: MCURF | CSE: MCUR)
Field Trip Health Ltd. (NASDAQ: FTRB | TSX: FTRP)
Novamind Inc. (OTCQB: NVMDF | CSE: NM)
BetterLife Pharma Inc. (OTCQB: BETRF | CSE: BETR)
MYND Life Sciences Inc. (Pink: MYNDF | CSE: MYND)
FSD Pharma Inc. (NASDAQ: HUGE | CSE: HUGE)
Mindset Pharma Inc. (OTCQB: MSSTF | CSE: MSET)
PsyBio Therapeutics Corp. (OTCQB: PSYBF | TSX-V: PSYB)
Psyched Wellness Ltd. (OTCQB: PSYCF | CSE: PSYC)
Bright Minds Biosciences Inc. (OTCQB: BMBIF | CSE: DRUG)
Cybin Inc. (NYSE American: CYBN | NEO: CYBN)
Mydecine Innovations Group (Pink: MYCOF | NEO: MYCO)
NeonMind Biosciences Inc. (OTCQB: NMDBF | CSE: NEON)
Numinus Wellness Inc. (TSX-V: NUMI)
Tryp Therapeutics Inc. (OTCQB: TRYPF | CSE: TRYP)
Wesana Health Holdings Inc. (OTCQB: WSNAF | CSE: WESA)
Filament Health Corp. (OTCQB: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

Posted on

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

NEW YORK, Oct. 18, 2021 /CNW/ – Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

REGISTER OR LOGIN NOW AT: https://bit.ly/3acCV7Y

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.

Presentations

Presentation

Ticker(s)

Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation

“Investing in Psychedelics and CNS Treatments”

       Lindsay Hoover, Partner, JLS Fund

       Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL), AdvisorShares Investments

       Tim Regan, SVP, KCSA Strategic Communications

Small Pharma Inc.

(Pink: DMTTF | TSX-V: DMT)

Awakn Life Sciences Corp.

(OTCQB: AWKNF | NEO: AWKN)

HMNC Brain Health

(Private Company)

Enveric Biosciences

(NASDAQ: ENVB)

Mind Cure Health Inc.

(OTCQX: MCURF | CSE: MCUR)

Field Trip Health Ltd.

(NASDAQ: FTRB |TSX: FTRP)

Novamind Inc.

(OTCQB: NVMDF | CSE: NM)


BetterLife Pharma Inc.

(OTCQB: BETRF | CSE: BETR)

MYND Life Sciences Inc.

(Pink: MYNDF | CSE: MYND)

FSD Pharma Inc.

(NASDAQ: HUGE | CSE: HUGE)

Mindset Pharma Inc.

(OTCQB: MSSTF | CSE: MSET)

PsyBio Therapeutics Corp.

(OTCQB: PSYBF | TSX-V: PSYB)

Psyched Wellness Ltd.

(OTCQB: PSYCF | CSE: PSYC)

Bright Minds Biosciences Inc.

(OTCQB: BMBIF | CSE: DRUG)

Cybin Inc.

(NYSE American: CYBN | NEO: CYBN)


Mydecine Innovations Group

(Pink: MYCOF | NEO: MYCO)

NeonMind Biosciences Inc.

(OTCQB: NMDBF | CSE: NEON)

Numinus Wellness Inc.

(TSX-V: NUMI)

Tryp Therapeutics Inc.

(OTCQB: TRYPF | CSE: TRYP)

Wesana Health Holdings Inc.

(OTCQB: WSNAF | CSE: WESA)

Filament Health Corp.

(OTCQB: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

For further information: Media Contact: OTC Markets Group Inc., (212) 896-4428, media@otcmarkets.com; Investor Contacts: John M. Viglotti, SVP Corporate Services, Investor Access, OTC Markets Group, (212) 220-2221, johnv@otcmarkets.com; Tim Regan/Allison Soss, KCSA Strategic Communications,(212) 682-6300, conference@kcsa.com

Posted on

Hey ladies, get those butterflies back with MDMA: issue 19

Here’s what’s in store for you in today’s issue:

🍄 Preventing depression legally

🍄 Inhaling shrooms?

🍄 The cure for low sex drive

🍄 Why your employer should let you do drugs

🍄 And more.

You’ll want to stay till the end to learn how someone found enlightenment on a trippy hike.

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast:
Psychedelic medicines could hold a promise never seen before in mental healthcare

In this episode we have Dave Philips, a registered clinical counselor who has integrated psychedelic therapy into his practice. Dave talks about how he is training the next generation of psychedelic counselors and how he started in this extraordinary field.

Therapeutic banner

How to prevent depression legally

Even non-psychedelic mushrooms could lower your risk of depression!

Researchers from the Penn State College of Medicine collected data from 24,000 Americans and discovered that those who ate mushrooms had a lower chance of being depressed.

Mushrooms are the highest dietary source of ergothioneine, an antioxidant that may prevent mental illnesses by reducing oxidative stress protecting against cell damage. 

While the study didn’t factor in different types of mushrooms, white buttons are believed to ease anxiety and Lion’s Mane can promote neurogenesis which may prevent mental disorders.

Therapy is hard…but drugs help!

Patients with treatment-resistant depression (TRD) often struggle with concentration, mood and motivation, which can make therapy challenging or unsuccessful. Can psilocybin’s immediate mood-boosting effect enhance engagement in therapy?
 
Monash University is seeking funding from the Australian government for a proposed 2b clinical trial that would reveal the answer.
 
The study would use proprietary biomarker technology developed by MYND Diagnostics Inc., a subsidiary of MYND Life Sciences (MYND), to monitor blood indicators of the subjects’ response, progress, and any relapsing to the psilocybin treatments. If successful, a multi-site phase 3 adaptive trial would follow within a year of completion to get psilocybin-assisted therapy approved by the Therapeutic Goods Association.

Never leave home without your inhaler 😉

Cybin Inc. (CYBN) developed a new device that delivers psychedelic medicine through inhalation.

Inhaling psychedelics could be superior to oral administration, as it could result in optimized session timing, lower doses, and greater control for healthcare providers.

The company filed an international patent application for the method and the device, which has potential to gain coverage in 153 countries.

inspirational banner

Is MDMA the Viagra for women?

A Vancouver company called LOVE Pharma (LUV) wants to promote mental and sexual wellness with its growing product line. 

The company recently launched two products (a CBD oral strip and a clitoral stimulation gel) and has exclusive rights to a total of seven novel therapeutic products. It’s currently developing a biosynthetic psilocybin strip using the IP from the CBD strip.

On Tuesday, the company was listed on  the Frankfurt Stock Exchange under the symbol “G1Q0”.

In other sexual wellness news, Mind Cure Health (MCUR) recently launched a research program to treat female hypoactive sexual desire disorder (HSDD), a disorder involving low sex drive and emotional distress, with MDMA-assisted therapy.

How shrooms are saving the butterflies!

An eye-opening psychedelic journey inspired this former Navy SEAL save the butterflies while helping veterans cope with trauma.

Mark Matzeldelaflor founded a nonprofit called Guardian Grange after a magic mushroom trip showed him the healing power of nature.

“I just reconnected to nature and my past, where I was like a kid in the woods. And I realized there’s so much healing in being outside in nature, getting your hands in the dirt and doing good work,” he said.

The organization provides a safety net for veterans where they can learn about conservation, sustainability and regenerative agriculture while transitioning back to civilian life. Its first major initiatives is to build a preserve for Western monarch butterflies, which have had a 99.9% population decline in California.

Why your employer should let you do drugs

Psych’s third annual report on psychedelic medicine revealed some interesting findings.

According to a survey of 440 healthcare professionals working in various fields, two thirds said they were excited about psychedelics as medicines. Of those who’ve personally tried the drugs for therapeutic or spiritual purposes, 83% were in favour of psychedelic medicine.

Consumers also showed a positive view of psychedelics, with about two thirds supporting medical legalization and 38% noting that someone they know would benefit from psychedelic therapy. When asked which psychedelic they would want to try in therapy, psilocybin and salvia were the most popular choices.

The report also showed that psychedelic therapy could save employers US$64 billion in Europe and US$270 billion in America due to fewer sick days and increased productivity.

business banner

New advisor supports expansion into psychedelic treatments

Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) is accelerating its expansion into psychedelic and mental health treatments with a new addition to its team.

Yesterday, Blackhawk appointed Dr. Lahiru Russell, the founder and chief scientist of Digital Health Technologies, as the company’s medical advisor. Using her 10+ years of experience in clinical trials and psycho-oncology research, Dr. Russel is developing a mindfulness-based intervention platform that will help patients regulate their emotions and thoughts to reduce negative mental health conditions.

Blackhawk’s subsidiary, MindBio Therapeutics, will be able to utilize Dr. Russel’s IP in its microdosing research through a commercialization agreement with Digital Mind Technology, which was established last month.

MindBio will also utilize Google Cloud’s “Health Care Solutions” to recruit, enroll, and engage with patients in its internal clinical trials and to accelerate drug development.

A new subsidiary to tackle depression

atai Life Sciences (ATAI) and Chymia LLC launched a new company to offer individualized care for patients with treatment-resistant depression (TRD).

The company, PsyProtix, takes a precision psychiatry approach – an emerging method that treats illnesses based on each patient’s genetic, metabolic, environmental, and lifestyle variability.

The platform should allow patients to be diagnosed and treated faster and more effectively than when following protocols designed for the majority.

Measuring brain penetration?

Mindset Pharma (MSET) is rapidly expanding its pipeline thanks to advancements made by its Co-operative Psychedelics Evaluation (COPE) program, which aims to develop preclinical benchmark data for psychedelic medicines.

Researchers established standard pharmacokinetic, brain penetration, and drug discrimination data and protocols for psilocybin, LSD, and 5-MeO-DMT. The company also developed procedures to determine concentrations of the drugs in plasma, brain, and cerebral spinal fluid.

These finding, which were gathered in collaboration with InterVivo Solutions, will help drug developers understand how compounds interact with the body. Mindset will commercialize the data by making it available to other InterVivo clients.

legal banner

Another win for California

With a unanimous vote, Arata became the third city in California to decriminalize psychedelics!

The possession, cultivation and distributions of entheogens including psilocybin and ayahuasca will become the city’s lowest law enforcement priority, but commercial sale will remain illegal.

The measure represents “a pivotal point in history by reclaiming our sovereign right to explore our consciousness, and to choose the path of healing that we see best fit for ourselves,” according to an organizer of the activist group Decriminalize Nature Humboldt.

We told you decriminalization isn’t risky!

It’s been over two years since Denver decriminalized mushrooms, and a recent report shows that people are using psilocybin responsibly.

The Denver Psilocybin Mushroom Policy Review Panel, which is comprised of local officials, law enforcement, and scientific experts, unanimously agreed that there have been no significant public health or safety risks as a result of the reform.

The panel proposed that the city’s next steps should be to train first responders to respond to psychedelic crises, create public service announcements on psychedelic safety, and deprioritize the sharing, gifting, and communal use of psilocybin, among other recommendations.

Support for first responders

The push for psilocybin research is gaining traction in Pennsylvania.

Twenty one lawmakers from both parties sponsored a bill called the Public Heath Benefits of Psilocybin Act, which would set up a research framework to optimize psilocybin’s public health benefits. Studies focused on veterans, retired first responders, and their families would be prioritized.

“A growing body of research provides a reason for hope that psilocybin, administered in a controlled setting, will be the most effective tool at our disposal to combat the suicide, opioid and overall mental health crisis burdening the Commonwealth,” the group wrote to colleagues.

Industry Quick Hits

Oct 8 – Numinus (NUMI) Upgrades Psychedelics Lab to Increase Research Service Capabilities Read more…

Oct 11 – Cannabis Global (CBGL) Selects Oakland, CA for New Mushroom-based Psychedelics Infusion Research Initiative Read more…

Oct 13 – Novamind (NM) Granted DEA Licenses for Psilocybin Research Read more…

Oct 13 – MindMed (MNMD) Joins Clinical Trials Transformation Initiative Read more…

Oct 13 – Psyence Group (PSYG) Announces Commencement Of Trading On OTCQB And DTC Eligibility Of Common Shares In The United States Under The Ticker “PSYGF” Read more…

Oct 14 – Delic Corp’s (DELC) Ketamine Wellness Centers Partners with Veterans Affairs Community Care Network to Provide Free Ketamine Treatments to Veterans Read more… 

Video of the Week

Thomas Hartle Advocates for Medical Psilocybin Regulations - TheraPsil

🌲+🌧️+🍄=✨

This Reddit user found enlightenment after taking a mega dose of Golden Teachers in the forest.

“I like to combine mushrooms and hiking. The forecast called for rain on this day. Generally not the best hiking weather, unless there’s shrooms involved.

Once they kicked in I went into this deep meditation. I started to think about current events in my life, but as if I was looking at them from a completely different set of eyes. I was so deep in meditation that I didn’t realize it had started raining. I slowly came to the realization that I was soaking wet. Normally that might have made me feel uncomfortable. I stood up and felt ready for anything this world could throw at me.

I looked around and the visualizations were quite extreme. All of the landscape around me was shifting and moving. It looked like the whole earth was breathing. The patterns in the bark of the trees were moving. I found this big rock under a tree and laid flat on my back. At this point it was raining pretty hard. I could feel every raindrop hitting my face. I could see the droplets falling through the sky as if it was slow motion. The raindrops dripping from the surrounding leaves and branches seemed to be frozen in time. My concept of time itself was totally lost. I felt like I had been laying under that tree for days.

It started to get dark and was still raining. I could hear thunder in the distance. The forest looked so enchanting and I felt like I was in the most magical place. I left the forest and watched the lightning in the distance until the trip wore off. I wasn’t even slightly bothered by the fact that I was totally drenched from head to toe.“

Playlist of the Week

Psychedelic rock
Posted on

Novamind Granted DEA Licenses for Psilocybin Research

Novamind Granted DEA Licenses for Psilocybin Research

Licenses a key step in hosting contracted clinical trials for Schedule 1 controlled substances

TORONTO, ON / October 13, 2021 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine is pleased to announce it has been granted Schedule 1 licenses (the “DEA Licenses”) from the U.S. Drug Enforcement Agency (DEA) for Dr. Reid Robison, Chief Medical Officer, and Dr. Paul Thielking, Chief Scientific Officer. The DEA Licenses are required for research sites planning to host clinical trials for psilocybin, enabling principal investigators to store and administer this controlled substance.

“Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy,” commented Dr. Robison. “We’re proud of our clinical research organization’s track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment.”

Psilocybin has shown significant positive outcomes for people with major depressive disorder1 and for reducing anxiety and depression in people with life-threatening cancer.2 As of today, there are over 50 clinical studies actively examining the use of psilocybin, as listed on www.clinicaltrials.gov.

“The DEA Licenses are timely,” said Dr. Thielking, who last week launched Psychedelic Palliative Care by Novamind, a first of its kind program to support the mental health of patients and families struggling with serious illness. “We anticipate that this progress will accelerate the approval process for us to become a research site for additional psychedelic clinical studies in the future.”

To learn more about Novamind’s clinical research division, visit www.cedarclinicalresearch.com.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

1: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630
2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/

Posted on

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestorConferences.com 

NEW YORK, Oct. 11, 2021 /CNW/ – Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.

“The psychedelics industry is poised to provide much needed therapies to address the global mental health crisis. Some of the companies presenting over the next two days may be the next Pfizer, Roche or Sanofi,” commented Lewis Goldberg, Managing Partner at KCSA Strategic Communications.

REGISTER NOW AT: https://bit.ly/3acCV7Y

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There are no fees to log-in, attend the live presentations or ask questions.

October 13th Agenda:  

Eastern
Time (ET)

Presentation

Ticker(s)

9:45 AM

KCSA Welcome Remarks

10:00 AM

Small Pharma Inc.

(Pink: DMTTF | TSX-V: DMT)

10:30 AM

Awakn Life Sciences Corp.

(OTCQB: AWKNF | NEO: AWKN)

11:00 AM

HMNC Brain Health

(Private Company)

11:30 AM

Enveric Biosciences

(NASDAQ: ENVB)

12:00 PM

Mind Cure Health Inc.

(OTCQX: MCURF | CSE: MCUR)

12:30 PM

Field Trip Health Ltd.

(NASDAQ: FTRB)

1:00 PM

Novamind Inc.

(OTCQB: NVMDF | CSE: NM)

1:30 PM


BetterLife Pharma Inc.

(OTCQB: BETRF | CSE: BETR)

2:00 PM

MYND Life Sciences Inc.

(Pink: MYNDF | CSE: MYND)

October 14th Agenda:

Eastern
Time (ET)

Presentation

Ticker(s)

9:55 AM

KCSA Opening Remarks

10:00 AM

Mindset Pharma Inc.

(OTCQB: MSSTF | CSE: MSET )

10:30 AM

PsyBio Therapeutics Corp.

(OTCQB: PSYBF | TSX-V: PSYB)

11:00 AM

Psyched Wellness Ltd.

(OTCQB: PSYCF | CSE: PSYC)

11:30 AM

Bright Minds Biosciences Inc.

(OTCQB: BMBIF | CSE: DRUG)

12:00 PM ET

Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation

12:30 PM ET

Lunch Panel – Hosted by KCSA’s Tim Regan “Investing in Psychedelics and CNS Treatments”

1:00 PM

Cybin Inc.

(NYSE American: CYBN | NEO: CYBN)

1:30 PM


Mydecine Innovations Group

(Pink: MYCOF | NEO: MYCO)

2:00 PM

NeonMind Biosciences Inc.

(OTCQB: NMDBF | CSE: NEON)

2:30 PM

Numinus Wellness Inc.

(TSX-V: NUMI)

3:00 PM

Tryp Therapeutics Inc.

(OTCQB: TRYPF | CSE: TRYP)

3:30 PM

Wesana Health Holdings Inc.

(OTCQB: WSNAF | CSE: WESA)

4:00 PM

Filament Health Corp.

(Pink: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

For further information: Media Contact: OTC Markets Group Inc., (212) 896-4428, media@otcmarkets.com; Investor Contacts: John M. Viglotti, SVP Corporate Services, Investor Access, OTC Markets Group, (212) 220-2221, johnv@otcmarkets.com; Tim Regan/Allison Soss, KCSA Strategic Communications, (212) 682-6300, conference@kcsa.com

Posted on

Novamind to Present at LD Micro and KCSA Conferences

Novamind to Present at LD Micro and KCSA Conferences

TORONTO, ON / October 8, 2021 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, today announced participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.

Novamind’s CEO and Director, Yaron Conforti, will present the Company’s progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of the Company’s sixth clinic and the newly launched Psychedelic Palliative Care program.

Virtual LD Micro Main Event XIV
Date: October 13, 2021
Time: 10:30 AM to 11:00 AM EST
Register and watch live here: me21.mysequire.com

KCSA Psychedelics Virtual Investor Conference
Date: October 13, 2021
Time: 1:00 PM to 1:30 PM EST
Register and watch live here: www.virtualinvestorconferences.com/events/event-details/psychedelics-virtual-investor-conference

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

Shrooms win the Seattle fight club: issue 18

Here’s what’s in store for you in today’s issue:

🍄 A trippy (family-friendly) vacay

🍄 Microdosing for pain management

🍄 Psychedelic beverages

🍄 The largest US city to decriminalize shrooms

🍄 And more.

You’ll want to stay till the end to learn how someone discovered their inner child with help from mischievous spirits!

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast:
Psychedelic medicines could hold a promise never seen before in mental healthcare

In this episode we have Dave Philips, a registered clinical counselor who has integrated psychedelic therapy into his practice. Dave talks about how he is training the next generation of psychedelic counselors and how he started in this extraordinary field.

Therapeutic banner

A trippy (family-friendly) vacay

Patients in palliative care have higher rates of depression – could a psychedelic retreat change this?

Launched yesterday in Utah, “Psychedelic Palliative Care by Novamind” combines psychedelic-assisted therapy with workshops, multi-day immersive retreats, and group support at its recently-opened clinic.

“Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies,” said Novamind’s Chief Scientific Officer.

Fight Club💥

Lobe Sciences (LOBE) is partnering with the the World Boxing Association (“WBA”) to help boxers manage brain injuries!

The organizations plan to launch a global registry to identify former and current boxers with mild traumatic brain injury (mTBI) and help them manage the side effects, which can often include PTSD. The WBA will also develop best practices for early diagnosis of mTBI that can be used immediately after fights for current boxers.

Injured boxers could potentially be treated with Lobe’s therapeutic regimen, which utilizes the combination of psilocybin and NAC (the pneumonia drug) mentioned in last week’s issue.

inspirational banner

E. coli + shroom moonshine anyone?

A recent study suggests that it’s possible to produce a potent “psilocybin moonshine” using a fast and simple homebrew method that doesn’t involve growing mushrooms or sterilization.

Researchers inserted magic mushroom genes into E. coli bacteria, which was then added to bottles, submerged in a water tank that was aerated with an aquarium pump, and covered with aluminum foil to maintain a temperature of 37 °C.

In less than two days, 300 mg of psilocybin was produced per liter of water. The method even worked without sterilization, but produced only 100 mg/L, yet this deficit was counteracted by adding a form of penicillin.

Even boomers want to microdose

New market research shows a growing interest in psilocybin services!

Red Light Oregon, a 50/50 joint venture between Red Light Holland (TRUFF) and Halo Collective (HALO), conducted market research to help the Oregon Psilocybin Advisory Board (OPAB) and health officials make informed regulations.

Of 473 Oregonian adults surveyed, 86% showed in interest in microdosing, including 94% of Gen Z and 74% of Boomers. As a result, Red Light Oregon launched an advocacy program to educate the OPAB and health officials on the benefits of microdosing.

The survey also found that 37% of adults, mainly minorities, did not know what psilocybin is, so the company is launching a community outreach program to educate underserved populations on psilocybin’s therapeutic effects.

Turn the music up, it’s sad boi hour

Scientists confirmed what mushroom users have long known…

In a study conducted by a Copenhagen University researcher, psilocybin was found to increase the emotional response to music, whereas the control drug, ketanserin (a blood pressure medication), lessened the emotional response.

Participants listened to 10 minutes of classical music and were assessed on the Geneva Emotional Music Scale, which measures nine mental states: wonder, transcendence, tenderness, nostalgia, peacefulness, power, joyful activation, tension, and sadness. Those on psilocybin showed a 60% increase in emotions.

“What we need to do now is optimize this approach probably through individualizing and personalizing music tracks in therapy,” says Professor David Nutt of Imperial College London.

business banner

New ways to consume drugs 🎉

Will shroom edibles and drinks be the next big thing in Cali?

Cannabis Global Inc. (CBGL) is developing methods to infuse psilocybin and psilocin, as well as other compounds found in psychedelic mushrooms, into foods and beverages.

The LA-based company has initiated research into infusion methods to improve bioavailability of the compounds and to mask the bitter flavour of the mushrooms. It has already filed 9 patent applications for its cannabinoid infusion technologies, which it hopes to leverage for this new research program.

With the state of California on track to have a psilocybin legalization measure on the 2022 ballot, the program could potentially serve a large marketplace in the near future.

Managing pain across the globe

Could microdosing + this new technology reduce pain in cancer patients?

MindBio Therapeutics is developing a technology platform to integrate with psychedelic therapy to prevent the mental health of cancer patients from deteriorating. By utilizing wearable devices, the platform is designed to help with pain management to prevent depression, existential distress, and anxiety.

MindBio Therapeutics will use the mindfulness app in an upcoming  Phase 2 microdosing trial, which is funded by the New Zealand government, to see if it provides additional benefits to late-stage cancer patients compared to microdosing alone.

The company aims to commercialize the application globally and believes the tech has potential to receive government funding in Europe.

More psilocybin please!

This new extraction method could yield more psilocybin from a single mushroom than previously possible.

Natural psilocybin extraction can have low and unstable yields, which is why many companies opt for synthetic versions. When mushrooms are dehydrated, the total psilocybin/psilocin content extracted is three times lower than the total amount believed to be in the mushroom.

Optimi Health (OPTI) developed an extraction technique that not only increases the yield of natural psilocybin, but also protects the compounds from degeneration while reducing the cost of the final drug. On Tuesday, the company announced that it filed a provisional patent application to protect the process.

legal banner

Seattle becomes the largest US city to decriminalize psychedelics

With a unanimous vote, a new legislation was passed to decriminalize the possession, cultivation, and sharing of psychedelic mushrooms, ayahuasca, ibogaine and non-peyote-derived mescaline.

Peyote was intentionally excluded from the measure, as it’s in danger of extinction due to the increase in illegal harvesting. In fact, Santa Cruz recently removed peyote and other mescaline-containing cacti from the city’s decriminalization policy after pushback from Indigenous groups that consider the entheogens to be sacred.

Psychedelic reform coming this year!

It’s time for the federal government to catch up with the rest of America. 

At a psychedelics policy symposium organized by Harvard’s Project on Psychedelics Law and Regulation (POPLAR), Rep. Earl Blumenauer (D-OR) said he plans to bring drug reform to the Capitol this year!

“I promise you I will do my part—not only assisting in the evolution of the Oregon [psilocybin] program, but I plan on bringing this movement to Capitol Hill this year in the same way we developed the foundation for the support of our cannabis work,” he vowed.

This is why Gen Z should be in charge…

Some of the youngest state legislators in the US want to decriminalize all drugs.

Tony Labranche, a 19-year-old Rep. of New Hampshire, is pushing to establish a regulated cannabis sales system and decriminalize the possession of magic mushrooms, as well as all other controlled substances. The reform proposals are bold for a GOP-controlled state, but they’re sparking more dialogue about the need to end the war on drugs.

Back in February, a 20-year-old lawmaker filed a bill to broadly decriminalize drug possession in Kansas, noting that drug use should be treated as a mental health problem rather than a criminal one.

Canada is following suit, with the city of Toronto preparing to ask Health Canada to decriminalize all drugs, similar to Vancouver’s request in May.

Progress down under

Australia’s Therapeutic Goods Administration (TGA) may reschedule psilocybin and MDMA after recognizing their therapeutic potential.

The substances are currently classified as Schedule 9, or “prohibited substances”, creating a barriers for conducting clinical research. The TGA is considering changing the classification to Schedule 8, or “controlled substances” (the same as THC) to allow controlled use in clinical settings.

The verdict will be announced in the first week of December after an advisory committee meeting!

Industry Quick Hits

Oct 1 – Psychedelic biotech startup Psylo raises $1.1m to treat mental health issues with psilocybin Read more…

Oct 4 – Incannex Healthcare (IHL) raises close to $18m, including $8m from chief medical officer Read more…

Oct 4 – Delix Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2021 Read more…

Oct 5 – Mydecine (MYCO) To Supply MYCO-001 for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson Read more…

Oct 5 – MindMed (MNMD) Announces Strategic Research Collaboration with Sphere Health Read more…

Oct 6 – Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio Read more… 

Oct 6 – Creso Pharma’s (CPH) psychedelics subsidiary proceeds to stability testing ahead of clinical trial Read more…

Oct 7 – Cybin (CYBN) Announces Milestone Achievements of its Subsidiary Adelia Therapeutics Read more…

Oct 7 – Tryp Therapeutics (TRYP) Announces Collaboration With Researchers At The University Of Wisconsin-Madison Read more… 

Oct 7 – PsyBio Therapeutics (PSYB) Successfully Demonstrates Commercial Scale Manufacturing Feasibility Read more…

Oct 7 – MYND Life Sciences (MYND) Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd. Read more…

Oct 7 – HAVN LIFE (HAVN) Files Final Base Shelf Prospectus Read more… 

Video of the Week

The 7 Basic Steps Of Mushroom Cultivation

Playing with mischievous spirits

This Reddit user found their inner child with help from some cheeky entities.

“On my first trip, I was taken to my afterlife and was touched by the unconditional universal love. It was so beautiful and I cry everytime I try to tell anyone about it because it felt so powerful. I’m crying now lol. I felt like I was in the presence of God. I was shown my Heaven and was told that there is nothing to fear about dying. I felt so much love from God towards me, it was overwhelming but very healing. It was like the love I feel for my children…. total acceptance, no judgement, unconditional positive regard.

On the next few trips I met a variety of more playful spirits who would ‘play’ with me like children would. Some were quite cheeky and mischievous. I called them my ragtag band of misfits. They really like to portray themselves to me as pirates. They helped to bring out the child in me and my sense of fun which I must admit I had burried deep inside due to life circumstances. My partner, who is my usual trip sitter, always hoped I would meet them because he liked seeing my cheeky side come out. My pirate friends liked him too and often made me say funny things to him, but they were always respectful towards him. Eventually, they stopped coming to me, to make way for higher beings who had other lessons to teach me. I miss those rascals and I hope to see them again some day.”

Playlist of the Week

Psychedlic and Chill
seattle mushroom
Posted on

A trippy (family-friendly) vacay

Novamind Launches New Psychedelic Palliative Care Program

Patients in palliative care have higher rates of depression – could a psychedelic retreat change this?

Yesterday, Novamind (NM) launched a first-of-its-kind program to help both patients and their families cope with terminal illness.

The program, called “Psychedelic Palliative Care by Novamind”, combines psychedelic-assisted therapy with workshops, multi-day immersive retreats, and group support at its recently-opened clinic in Murray, Utah.

“Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies,” said Novamind’s Chief Scientific Officer.

PDF of article

Posted on

Novamind Launches New Psychedelic Palliative Care Program

Novamind Launches New Psychedelic Palliative Care Program

Specialized program to research and scale access to psychedelic medicine opens new doors for patients with chronic and serious illness

TORONTO, ON / October 7, 2021 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to launch Psychedelic Palliative Care by Novamind (the “Palliative Program”) at its recently opened clinic and research site in Murray, Utah.

Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness.

“Patients receiving palliative care have higher rates of depression than the general population. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work,” explained Dr. Paul Thielking, Chief Scientific Officer (CSO) of Novamind. “Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies.”

Through Novamind’s clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin’s significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients.

Prior to his role as Novamind’s CSO, Dr. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Dr. Thielking leads the Palliative Program’s multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy.

“Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness,” noted Dr. Thielking. “Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment.”

To learn more about the Palliative Program, visit www.novamind.ca/psychedelic-palliative-care

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.